“Unecritinib (TQ-B3101)” (trade name: Amberni), a Class 1 innovative drug independently developed by the Group, has obtained marketing approval from the China National Drug Administration for the treatment of ROS1-positive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). This is the first domestically produced targeted drug approved for the treatment of ROS1-positive adult patients with locally advanced or metastatic non-small cell lung cancer.
中国生物制药：1类创新药富马酸安奈克替尼胶囊“UNECRITINIB (TQ-B3101)”获批上市
China Biopharmaceutical: Class 1 innovative drug anectinib fumarate capsules “UNECRITINIB (TQ-B3101)” approved for marketing
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.